Literature DB >> 30072129

Sex Differences of Patients With Systemic Hypertension (From the Analysis of the Systolic Blood Pressure Intervention Trial [SPRINT]).

Roberto Ochoa-Jimenez1, Karolina Viquez-Beita2, Chathuri Daluwatte1, Robbert Zusterzeel3.   

Abstract

There are differences in the incidence, pathophysiology, and long-term effects of hypertension between women and men. We assessed sex-specific benefit-risk tradeoffs of different blood pressure (BP) goals in patients enrolled in the Systolic Blood Pressure Intervention Trial (SPRINT) after propensity score matching those with standard therapy (systolic BP <140 mm Hg) to those with intensive therapy (systolic BP <120 mm Hg; n = 9,106). Cox regression was conducted to compare standard versus intensive therapy in women and men with the composite outcome of myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes. Women were generally healthier at baseline and had a lower cardiovascular risk. Men on intensive therapy had a lower risk of the composite outcome compared to those on standard therapy (hazard ratio [HR] 0.70, 95% confidence interval [CI] 0.57 to 0.86, p = 0.001) while in women no differences between therapy groups were observed (HR 0.82 [0.60 to 1.12], p = 0.206). For safety outcomes, women and men had increased risk of related serious adverse events with intensive treatment (HR 1.52 [1.06 to 2.18], p = 0.023 and HR 2.07 [1.55 to2.77], p < 0.001, respectively). In conclusion, our study demonstrated that women did not benefit from intensive compared to standard BP control. A potential explanation for this may be the lower baseline cardiovascular risk in women.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30072129     DOI: 10.1016/j.amjcard.2018.05.046

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

Review 1.  Sex, Oxidative Stress, and Hypertension: Insights From Animal Models.

Authors:  Jane F Reckelhoff; Damian G Romero; Licy L Yanes Cardozo
Journal:  Physiology (Bethesda)       Date:  2019-05-01

Review 2.  Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review.

Authors:  Leslie Cho; Melinda Davis; Islam Elgendy; Kelly Epps; Kathryn J Lindley; Puja K Mehta; Erin D Michos; Margo Minissian; Carl Pepine; Viola Vaccarino; Annabelle Santos Volgman
Journal:  J Am Coll Cardiol       Date:  2020-05-26       Impact factor: 24.094

3.  Characterizing Diagnostic Inertia in Arterial Hypertension With a Gender Perspective in Primary Care.

Authors:  Vicente Pallares-Carratala; Concepcion Carratala-Munuera; Adriana Lopez-Pineda; Jose Antonio Quesada; Vicente Gil-Guillen; Domingo Orozco-Beltran; Jose L Alfonso-Sanchez; Jorge Navarro-Perez; Jose M Martin-Moreno
Journal:  Front Cardiovasc Med       Date:  2022-06-16

Review 4.  Sex Differences in Hypertension: Where We Have Been and Where We Are Going.

Authors:  Lindsey A Ramirez; Jennifer C Sullivan
Journal:  Am J Hypertens       Date:  2018-11-13       Impact factor: 2.689

Review 5.  Sex Differences in the Prevalence, Outcomes and Management of Hypertension.

Authors:  Paul J Connelly; Gemma Currie; Christian Delles
Journal:  Curr Hypertens Rep       Date:  2022-03-07       Impact factor: 4.592

6.  Age and sex specific target of blood pressure for the prevention of cardiovascular event among the treatment naive hypertensive patients.

Authors:  Hyoungnae Kim; Seulbi Lee; Eunhee Ha; Soon Hyo Kwon; Jin Seok Jeon; Hyunjin Noh; Dong Cheol Han; Hyung Jung Oh; Dong-Ryeol Ryu
Journal:  Sci Rep       Date:  2020-12-09       Impact factor: 4.379

7.  Sex differences in workload-indexed blood pressure response and vascular function among professional athletes and their utility for clinical exercise testing.

Authors:  Pascal Bauer; Lutz Kraushaar; Oliver Dörr; Holger Nef; Christian W Hamm; Astrid Most
Journal:  Eur J Appl Physiol       Date:  2021-03-12       Impact factor: 3.346

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.